Merck Sees Decades-Long Time Horizon For Novel Antibiotics

Merck is one of the few big pharmas still investing in early-stage antibiotic R&D and is focusing long term on novel antibody and small molecule approaches, but Infectious Disease Research VP Daria Hazuda predicts the timeline for delivering innovative breakthroughs will be long.

Antimicrobial testing

Although many big pharmas have abandoned the clinically and commercially challenging field of antibiotics, Merck & Co. Inc. is one of the few continuing to invest in early-stage R&D in the therapeutic area. But developing novel antibiotic approaches beyond known mechanisms is a long-term proposition that could take a decade or more to deliver, VP-Infectious Diseases Research Daria Hazuda said in an interview.

“It’s pretty clear there are fewer and fewer people in large companies working in this area, both in the antibiotic...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category